Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study
{{output}}
Background: Patients with transthyretin amyloidosis (ATTR) with cardiomyopathy (CM) can experience extracardiac manifestations, including gastrointestinal (GI) manifestations that negatively impact their quality of life. ... ...
